"Our company has a track record of staying commited to the markets we serve. We are delighted to make a beginning towards serving the unmet needs of patients in Colombia," Dr Reddy's Laboratories Executive Vice President and Head Branded Markets-Global Generics MV Ramana said in a regulatory filing.
The Hyderabad-based firm operates in all major markets including the US, Russia, CIS countries and Europe with a workforce of above 20,000 employees.
Currently, Dr Reddy's is the second largest generic oncology injectable company by value in the US and leading generic oncology firm in India.
The company's shares today ended at Rs 3,054.35 apiece on the BSE, down 0.76 per cent from previous close.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)